Stark, Wiebke

[["dc.bibliographiccitation.journal","Multiple Sclerosis Journal"],["dc.bibliographiccitation.volume","22"],["dc.contributor.author","Huppke, Peter"],["dc.contributor.author","Hummel, H. M."],["dc.contributor.author","Stark, W."],["dc.contributor.author","Gaertner, J."],["dc.date.accessioned","2018-11-07T10:08:46Z"],["dc.date.available","2018-11-07T10:08:46Z"],["dc.date.issued","2016"],["dc.description.sponsorship","Bayer Vital; Biogen Idec; Novartis; Biogen"],["dc.format.extent","99"],["dc.identifier.isi","000383267201025"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/39532"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Sage Publications Ltd"],["dc.publisher.place","London"],["dc.relation.eventlocation","London, ENGLAND"],["dc.relation.issn","1477-0970"],["dc.relation.issn","1352-4585"],["dc.title","Fingolimod in active pediatric onset multiple sclerosis"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","119"],["dc.bibliographiccitation.journal","Journal of Neurology"],["dc.bibliographiccitation.lastpage","122"],["dc.bibliographiccitation.volume","255"],["dc.contributor.author","Stark, Wiebke"],["dc.contributor.author","Huppke, Peter"],["dc.contributor.author","Gärtner, Jutta"],["dc.date.accessioned","2017-09-07T11:48:07Z"],["dc.date.available","2017-09-07T11:48:07Z"],["dc.date.issued","2008"],["dc.description.abstract","Multiple sclerosis (MS) is a chronic inflammatory demyelinating disorder of the central nervous system and the most common disabling neurological disease in young adults. An estimated 5% of MS patients already have first clinical symptoms before the age of 16 years (paediatric MS). In the paediatric age group comprehensive analysis of the natural clinical course and the course under treatment in a large MS cohort is still missing. We describe a cohort of paediatric MS patients treated in the German Centre for Multiple Sclerosis in Childhood and Adolescence. A total of 166 patients with definite MS who are registered in our database were analysed. The observation time was up to 14.9 years with a mean follow-up of 4.1 years. Median age was 12.4 years (range 4 to 18 years). Prior to puberty the gender ratio was almost equal, while in adolescence there was a strong female predominance as is seen in adult onset MS. Almost all patients presented with relapsing-remitting MS. The course of the disease was more benign than in adult MS with a very slow EDSS increase and complete remission after most relapses. Most patients received immunomodulative treatment with interferon-beta or glatiramer acetate and, in severe cases, natalizumab. However, adequate treatment guidelines for this age group are still lacking."],["dc.identifier.doi","10.1007/s00415-008-6022-x"],["dc.identifier.gro","3143202"],["dc.identifier.isi","000263166600021"],["dc.identifier.pmid","19300972"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/690"],["dc.notes.intern","WoS Import 2017-03-10"],["dc.notes.status","final"],["dc.notes.submitter","PUB_WoS_Import"],["dc.publisher","Dr Dietrich Steinkopff Verlag"],["dc.relation.issn","0340-5354"],["dc.title","Paediatric multiple sclerosis: The experience of the German Centre for Multiple Sclerosis in Childhood and Adolescence"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.subtype","original"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","MULTIPLE SCLEROSIS"],["dc.bibliographiccitation.volume","13"],["dc.contributor.author","Stark, W."],["dc.contributor.author","van Rossum, D."],["dc.contributor.author","Rosenberger, Albert"],["dc.contributor.author","Bickeboeller, Heike"],["dc.contributor.author","Brueck, Wolfgang"],["dc.contributor.author","Gaertner, J."],["dc.date.accessioned","2018-11-07T10:58:20Z"],["dc.date.available","2018-11-07T10:58:20Z"],["dc.date.issued","2007"],["dc.format.extent","S200"],["dc.identifier.isi","000251423400617"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/50455"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Sage Publications Ltd"],["dc.publisher.place","London"],["dc.relation.conference","23rd Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis/12th Annual Conference of Rehabilitation in MS"],["dc.relation.eventlocation","Prague, CZECH REPUBLIC"],["dc.relation.issn","1352-4585"],["dc.title","Influence of gene polymorphisms on MS susceptibility and clinical presentation in childhood multiple sclerosis patients"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","32"],["dc.bibliographiccitation.issue","12"],["dc.bibliographiccitation.journal","DNP - Der Neurologe und Psychiater"],["dc.bibliographiccitation.lastpage","40"],["dc.bibliographiccitation.volume","17"],["dc.contributor.author","Schiller, Stina"],["dc.contributor.author","Stark, Wiebke"],["dc.contributor.author","Gärtner, Jutta"],["dc.date.accessioned","2017-11-28T09:52:30Z"],["dc.date.available","2017-11-28T09:52:30Z"],["dc.date.issued","2016"],["dc.description.abstract","Die Multiple Sklerose gehört zu den häufigsten neurologischen Erkrankungen des jungen Erwachsenenalters. Bis zu 5 % der Patienten erkranken jedoch bereits vor ihrem 16. Lebensjahr. Ätiologie und Pathogenese entsprechen mit hoher Wahrscheinlichkeit der adulten Form, dennoch stellt die pädiatrische MS aufgrund des frühen Erkrankungsbeginns für Patienten, Angehörige und Ärzte eine Herausforderung dar."],["dc.identifier.doi","10.1007/s15202-016-1061-0"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/10572"],["dc.language.iso","de"],["dc.notes.status","final"],["dc.relation.eissn","2196-6427"],["dc.relation.issn","1616-2455"],["dc.title","Was bei der pädiatrischen multiplen Sklerose zu beachten ist"],["dc.type","journal_article"],["dc.type.internalPublication","unknown"],["dc.type.peerReviewed","unknown"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","67"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Monatsschrift Kinderheilkunde"],["dc.bibliographiccitation.lastpage","77"],["dc.bibliographiccitation.volume","157"],["dc.contributor.author","Stark, W."],["dc.contributor.author","Gaertner, J."],["dc.date.accessioned","2018-11-07T08:35:09Z"],["dc.date.available","2018-11-07T08:35:09Z"],["dc.date.issued","2009"],["dc.description.abstract","Multiple sclerosis (MS) is a chronic inflammatory demyelinating disorder of the central nervous system of unknown etiology normally affecting young adults. Approximately 3-5% of MS patients have onset before the age of 16 (pediatric MS). Neurological deficiencies can occur in multifocal localisations. McDonald's criteria include the dissemination in space and time of the disease activity. Symptoms include, for example, visual dysfunction and sensory or motor impairments. The most frequent clinical manifestation in the pediatric group is a relapsing-remitting disease course, with a milder course of disease and a lower rate of progression when compared to adult MS. Typical diagnostic findings are periventricular lesions of the white matter, oligoclonal bands in the cerebrospinal fluid and delayed evoked potentials. Relapses are treated with high-dose methylprednisolone. Prophylactic, immunomodulative therapies as suggested for adult MS patients are also used for children."],["dc.identifier.doi","10.1007/s00112-008-1915-4"],["dc.identifier.isi","000262677700014"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/17992"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.relation.issn","0026-9298"],["dc.title","Pediatric multiple sclerosis (encephalomyelitis disseminata)"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","S163"],["dc.bibliographiccitation.issue","9"],["dc.bibliographiccitation.journal","MULTIPLE SCLEROSIS"],["dc.bibliographiccitation.lastpage","S164"],["dc.bibliographiccitation.volume","15"],["dc.contributor.author","Neuhaus, A."],["dc.contributor.author","Dreha-Kulaczewski, S. F."],["dc.contributor.author","Strobl, R."],["dc.contributor.author","Merkle, K."],["dc.contributor.author","Stark, W."],["dc.contributor.author","Sailer, M."],["dc.contributor.author","Brueck, Wolfgang"],["dc.contributor.author","Daumer, M."],["dc.contributor.author","Gaertner, J."],["dc.date.accessioned","2018-11-07T11:25:14Z"],["dc.date.available","2018-11-07T11:25:14Z"],["dc.date.issued","2009"],["dc.identifier.isi","000269652500487"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/56582"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Sage Publications Ltd"],["dc.publisher.place","London"],["dc.relation.conference","25th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis"],["dc.relation.eventlocation","Dusseldorf, GERMANY"],["dc.relation.issn","1352-4585"],["dc.title","Steps towards a German register in childhood multiple sclerosis"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","727"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","American Journal of Medical Genetics. Part A"],["dc.bibliographiccitation.lastpage","732"],["dc.bibliographiccitation.volume","173"],["dc.contributor.author","Burgemeister, Anna Lena"],["dc.contributor.author","Daumiller, Eva"],["dc.contributor.author","Dietze-Armana, Ilona"],["dc.contributor.author","Klett, Christine"],["dc.contributor.author","Freiberg, Clemens"],["dc.contributor.author","Stark, Wiebke"],["dc.contributor.author","Lingen, Michael"],["dc.contributor.author","Centonze, Izabela"],["dc.contributor.author","Rettenberger, Günther"],["dc.contributor.author","Mehnert, Karl"],["dc.contributor.author","Zirn, Birgit"],["dc.date.accessioned","2018-10-09T07:32:43Z"],["dc.date.available","2018-10-09T07:32:43Z"],["dc.date.issued","2017-03"],["dc.description.abstract","Constitutional ring chromosomes can be found for all human chromosomes and are very rare chromosomal abnormalities. A complete ring chromosome without loss of genetic material results from fusion of subtelomeric regions or telomere-telomere fusion. In cases of complete ring chromosome, an increased incidence of severe growth failure with no or only minor anomalies has been observed and attributed to ring syndrome. Ring syndrome is thought to be caused by \"dynamic mosaicism\" due to ring instability. We report a 6-year-old boy with de novo ring chromosome 4 and typical characteristics of the ring syndrome, namely, proportionate severe growth failure, microcephaly, and minor anomalies. Cytogenetic studies showed complete ring chromosome 4 with mitotic instability. Microarray gave normal results, thus excluding the loss of detectable genetic material. The literature of complete ring chromosome 4 is reviewed. Our case report supports the theory of ring syndrome. No studies about the effects and possible side effects of growth hormone therapy on patients with ring chromosomes have yet been published. We suggest that cytogenetic monitoring of the rate of secondary aberrations in patients with ring chromosome undergoing growth hormone therapy might be feasible. Since the diagnosis would have been missed by molecular karyotyping, our case report underlines the continuing role of classical cytogenetics for the evaluation of structural chromosomal abnormalities in patients with mental and/or physical anomalies. Standard karyotyping is still indispensable and should have an ongoing role as first-tier analysis together with molecular karyotyping. © 2017 Wiley Periodicals, Inc."],["dc.fs.pkfprnr","19400"],["dc.identifier.doi","10.1002/ajmg.a.38063"],["dc.identifier.fs","632451"],["dc.identifier.pmid","28127864"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/15896"],["dc.language.iso","en"],["dc.notes.status","final"],["dc.relation.eissn","1552-4833"],["dc.title","Continuing role for classical cytogenetics: Case report of a boy with ring syndrome caused by complete ring chromosome 4 and review of literature"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","382"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","Multiple Sclerosis"],["dc.bibliographiccitation.lastpage","387"],["dc.bibliographiccitation.volume","21"],["dc.contributor.author","Huppke, Peter"],["dc.contributor.author","Hummel, Hannah-Maria"],["dc.contributor.author","Ellenberger, David"],["dc.contributor.author","Pfeifenbring, Sabine"],["dc.contributor.author","Stark, Wiebke"],["dc.contributor.author","Huppke, Brenda"],["dc.contributor.author","Brueck, Wolfgang"],["dc.contributor.author","Gärtner, Jutta"],["dc.date.accessioned","2017-09-07T11:44:28Z"],["dc.date.available","2017-09-07T11:44:28Z"],["dc.date.issued","2014"],["dc.description.abstract","Background: Because of the emergence of novel therapies for multiple sclerosis (MS) and the associated increased risk of progressive multifocal leukoencephalopathy, John Cunningham (JC) virus infection has become a focus of interest for neurologists. However, little is known about JC virus infection in pediatric MS to date. Objective: We aimed to analyze the prevalence of anti-JC virus antibodies, the conversion rate and the influence of the anti-JC virus antibody status on the clinical course in a large pediatric MS cohort. Methods: Anti-JC virus antibodies were analyzed in serum samples within six months of disease onset and during the course of the disease. Clinical data were extracted from a pediatric MS databank. Results: A total of 51.6% of 256 patients were found to be positive for anti-JC virus antibodies at onset of disease. No correlation between antibody status and clinical course was seen. Analyzing 693 follow-up serum samples revealed high titer stability, and an annual conversion rate of 4.37% was seen. Conclusion: No evidence was found that seropositivity for anti-JC virus antibodies influences the clinical course. Surprisingly, seroprevalence for anti-JC virus antibodies was more than twice as high as anticipated in this age group, raising the question of whether the infection increases the risk of MS development."],["dc.identifier.doi","10.1177/1352458514543340"],["dc.identifier.gro","3141931"],["dc.identifier.isi","000352165000006"],["dc.identifier.pmid","25070674"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/2668"],["dc.notes.intern","WoS Import 2017-03-10"],["dc.notes.status","final"],["dc.notes.submitter","PUB_WoS_Import"],["dc.relation.eissn","1477-0970"],["dc.relation.issn","1352-4585"],["dc.title","JC virus antibody status in a pediatric multiple sclerosis cohort: Prevalence, conversion rate and influence on disease severity"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.subtype","original"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","17"],["dc.bibliographiccitation.journal","Manual Therapy"],["dc.bibliographiccitation.lastpage","24"],["dc.bibliographiccitation.volume","23"],["dc.contributor.author","Luedtke, Kerstin"],["dc.contributor.author","Boissonnault, W."],["dc.contributor.author","Caspersen, N."],["dc.contributor.author","Castien, R."],["dc.contributor.author","Chaibi, A."],["dc.contributor.author","Falla, Deborah"],["dc.contributor.author","Fernandez-de-las-Penas, Cesar"],["dc.contributor.author","Hall, T."],["dc.contributor.author","Hirsvang, J. R."],["dc.contributor.author","Horre, T."],["dc.contributor.author","Hurley, D."],["dc.contributor.author","Jull, Gwendolen"],["dc.contributor.author","Kroll, L. S."],["dc.contributor.author","Madsen, B. K."],["dc.contributor.author","Mallwitz, J."],["dc.contributor.author","Miller, C."],["dc.contributor.author","Schaefer, B."],["dc.contributor.author","Schoettker-Koeniger, T."],["dc.contributor.author","Starke, W."],["dc.contributor.author","von Piekartz, H."],["dc.contributor.author","Watson, D."],["dc.contributor.author","Westerhuis, P."],["dc.contributor.author","May, A."],["dc.date.accessioned","2018-11-07T10:13:46Z"],["dc.date.available","2018-11-07T10:13:46Z"],["dc.date.issued","2016"],["dc.description.abstract","Background: A wide range of physical tests have been published for use in the assessment of musculoskeletal dysfunction in patients with headache. Which tests are used depends on a physiotherapist's clinical and scientific background as there is little guidance on the most clinically useful tests. Objectives: To identify which physical examination tests international experts in physiotherapy consider the most clinically useful for the assessment of patients with headache. Design/methods: Delphi survey with pre-specified procedures based on a systematic search of the literature for physical examination tests proposed for the assessment of musculoskeletal dysfunction in patients with headache. Results: Seventeen experts completed all three rounds of the survey. Fifteen tests were included in round one with eleven additional tests suggested by the experts. Finally eleven physical examination tests were considered clinically useful: manual joint palpation, the cranio-cervical flexion test, the cervical flexion-rotation test, active range of cervical movement, head forward position, trigger point palpation, muscle tests of the shoulder girdle, passive physiological intervertebral movements, reproduction and resolution of headache symptoms, screening of the thoracic spine, and combined movement tests. Conclusions: Eleven tests are suggested as a minimum standard for the physical examination of musculoskeletal dysfunctions in patients with headache. (C) 2016 Elsevier Ltd. All rights reserved."],["dc.description.sponsorship","Deutsche Migrane-und Kopfschmerzgesellschaft (DMKG)"],["dc.identifier.doi","10.1016/j.math.2016.02.010"],["dc.identifier.isi","000376516500014"],["dc.identifier.pmid","27183831"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/40496"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Churchill Livingstone"],["dc.relation.issn","1532-2769"],["dc.relation.issn","1356-689X"],["dc.title","International consensus on the most useful physical examination tests used by physiotherapists for patients with headache: A Delphi study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","S10"],["dc.bibliographiccitation.journal","Aktuelle Neurologie"],["dc.bibliographiccitation.lastpage","S12"],["dc.bibliographiccitation.volume","39"],["dc.contributor.author","Stark, W."],["dc.contributor.author","Gaertner, J."],["dc.date.accessioned","2018-11-07T09:10:33Z"],["dc.date.available","2018-11-07T09:10:33Z"],["dc.date.issued","2012"],["dc.description.abstract","We describe a boy with first symptoms of childhood multiple sclerosis (MS) at the age of 11 years. The diagnosis MS was established after the second attack and a disease-modifying therapy was started with glatiramer acetate (Copaxone (R)). Due to high frequency of relapses and a progressing lesion load in cerebral MRI a conversion to interferon beta-1b (Betaferon (R)) was initiated and well tolerated. After a short stable period of disease further progression of MS has now occurred."],["dc.identifier.doi","10.1055/s-0032-1304871"],["dc.identifier.isi","000305870900004"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/26516"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Georg Thieme Verlag Kg"],["dc.relation.issn","0302-4350"],["dc.title","Paediatric Patient with Multiple Sclerosis and High Disease Activity"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]